Navigation Links
Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
Date:7/7/2009

no longer respond to the standard of care under Fast Track designation from the U.S. Food and Drug Administration.

About Carcinoid Syndrome

Carcinoid syndrome is a chronic condition caused by metastatic neuroendocrine tumors that usually originate from the gastrointestinal tract. These tumors secrete large amounts of serotonin, which can cause a variety of symptoms including severe diarrhea and abdominal discomfort. Patients with carcinoid syndrome currently have limited therapeutic options, and the standard of care includes chronic therapy with somatostatin analogues, which are delivered by injection. With current therapy, the gastrointestinal symptoms return over time in the vast majority of patients, hence the need for new agents.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease. Lexicon currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which were discovered by the company's research team. The company has used its proprietary gene knockout technology to identify more than 100 promising drug targets. Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs. For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's clinical development of LX1032 and the potential therapeutic and commercial potential of LX1032. This press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
2. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
3. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2009 Financial Results on April 28, 2009
4. Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online
5. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
6. Lexicon to Report Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
7. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
8. Lexicon Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
9. Lexicon Pharmaceuticals to Present at the Piper Jaffray 19th Annual Health Care Conference
10. Lexicon Pharmaceuticals Reports 2007 Third Quarter Financial Results
11. Lexicon to Report Third Quarter 2007 Financial Results on October 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2013)... MA (PRWEB) May 19, 2013 The ... social media training online, has proudly announced that the ... small business has surpassed 175,000 views on YouTube. The ... social media and SEO tips and training for small ... my students find the YouTube tips helpful for their ...
(Date:5/17/2013)... rejection occurs when the transplant recipient,s immune system identifies ... It was previously thought that T cells, the immune ... molecules known as chemokines in order to migrate to ... Journal of Clinical Investigation , Fadi Lakkis and colleagues ... that chemokine stimulation of T cells is not required ...
(Date:5/17/2013)... USA (PRWEB) May 17, 2013 •    First ... Globes Certified for sustainability ,     New facility will ... , Syngenta unveiled its new ... at the company’s RTP Innovation Center. The first of ... researchers to simulate any agricultural climate and precisely measure ...
(Date:5/17/2013)... , May 17, 2013 /PRNewswire-iReach/ -- Aridis is ... reached with Switzerland -based Kenta ... human monoclonal antibody (mAb) products, and technologies. This ... products for treatment of infections by common pathogens ... aureus , Pseudomonas aeruginosa , Acinetobacter ...
Breaking Biology Technology:YouTube Channel on SEO Tips Surpasses 175,000 Views, Announces JM Internet Group 2Syngenta Opens Unique $72 Million Advanced Crop Lab 2Syngenta Opens Unique $72 Million Advanced Crop Lab 3Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3
... and TORONTO, Nov. 13 /PRNewswire/ - BioRelix, ... based therapeutic agents and,Dalton Medicinal Chemistry, have ... therapeutics. Dalton Medicinal Chemistry will utilize ... novel classes of compounds against selected,RiboSwitch targets. ...
... Patients suffering from a range of debilitating illnesses, such as ... and ataxia stand to benefit from a new laboratory, established, ... China at the,forefront of the global race to engineer and reprogram ... ...
... Equity Research, Inc.,(Scimitar) issues a review of Neurobiological ... Viprinex(TM) Mission by a,Successful $60m Offering; Mountains Do ... website: http://www.scimitarequity.com . Neurobiological Technologies, Inc. ... of acquiring and developing central nervous system,related drug ...
Cached Biology Technology:BioRelix and Dalton Medicinal Chemistry Sign Research Agreement to Capitalize on RiboSwitch Technology 2Stem Cell Leader Beike Biotech and China's Tsinghua University Receive US$4 Million for Stem Cell Reprogramming Laboratory 2Stem Cell Leader Beike Biotech and China's Tsinghua University Receive US$4 Million for Stem Cell Reprogramming Laboratory 3Stem Cell Leader Beike Biotech and China's Tsinghua University Receive US$4 Million for Stem Cell Reprogramming Laboratory 4Neurobiological Technologies, Inc. (Nasdaq: NTII) Q1/08 Review Issued By Scimitar Equity Research, Inc. 2
(Date:5/16/2013)... scientist has discovered an ancient extinct creature with ,scissor ... in honour of his favourite movie star. , ... deppi (pronounced Koo-ten-ee-che-la depp-eye), which is a distant ... actor Johnny Depp for his starring role as Edward ... Edward, an unfinished creation, who has scissors for hands. ...
(Date:5/16/2013)... world are meeting next week in Toronto. The ... latest in research findings about the brain, the ... disorders that affect them., "Canada is a leader ... the best of neuroscience research done here and ... the Canadian Association for Neuroscience. He also reminds ...
(Date:5/16/2013)... -- The consultancy Frost & Sullivan presented ... Germany,s largest biometrics manufacturer, DERMALOG Identification ... DERMALOG has been honored yesterday night by Frost ... category Global Biometrics and Border Control  Customer Value Enhancement ... Control System . One of the decisive factors in ...
Breaking Biology News(10 mins):Actor Johnny Depp immortalized in ancient fossil find 27th Annual Canadian Neuroscience Meeting, Toronto, May 20-24, 2013 2Global Biometrics and Border Control Award for DERMALOG 2Global Biometrics and Border Control Award for DERMALOG 3Global Biometrics and Border Control Award for DERMALOG 4
... Development, Dr. Mary Ellen Perry and colleagues validate the ... therapies. , The p53 tumor suppressor plays a critical ... to activate p53 in order to curb tumor formation. ... an attractive target to modulate p53 activity in cells. ...
... Prostaglandins ?the fat-derived compounds linked to pain, inflammation, ... to their extensive catalog. , A new study ... the intricate cell movements during early embryonic development ... might influence human development and the spread of ...
... With an equal rate of incidence and mortality-the number of ... die from it-Glioblastoma Multiforme (GBM) is a brain cancer death ... with GBM annually in the U.S., half will die within ... only treatments that stretch survival limits are exceptionally invasive surgeries ...
Cached Biology News:Study fishes out new role for prostaglandins 2Study fishes out new role for prostaglandins 3Radiotherapy advance points way to noninvasive brain cancer treatment 2Radiotherapy advance points way to noninvasive brain cancer treatment 3